Table 2.
bivariate analysis of patients’ characteristics and timing of tumour recurrence (n = 55)
| Recurrence | |||
|---|---|---|---|
| Characteristics | Early (%) | Late (%) | P-value |
| Age, in years | 0.108a | ||
| <50 | 7 (23.3) | 9 (36.0) | |
| ≥50 | 23 (76.7) | 16 (64.0) | |
| Mean age ± SD | 56.9 ± 10.2 | 51.9 ± 12.4 | |
| Menopausal status | 0.843 | ||
| Premenopause | 14 (46.7) | 11 (44.0) | |
| Postmenopause | 16 (53.3) | 14 (56.0) | |
| Parity | 0.600b | ||
| Low | 7 (23.3) | 12 (48.0) | |
| High | 23 (76.7) | 13 (52.0) | |
| Median parity (IQR) | 2.0 (1.8, 3.0) | 2.0 (0.0, 4.0) | |
| Body Mass Index (BMI), in kg/m2 | 0.846b | ||
| ≤25.0 | 14 (46.7) | 12 (48.0) | |
| >25.0 | 16 (53.3) | 13 (52.0) | |
| Median BMI (IQR) | 25.2 (23.6, 29.7) | 26.1 (21.0, 33.2) | |
| Co-morbidity | 0.012 | ||
| No | 25 (83.3) | 13 (52.0) | |
| Yes | 5 (16.7) | 12 (48.0) | |
| Pre-treatment CA125 levels, in U/mL | 0.147b | ||
| <250.0 | 7 (23.3) | 5 (20.0) | |
| ≥250.0 | 23 (76.7) | 20 (80.0) | |
| Median CA125 (IQR) | 443.1 (339.0, 1110.0) | 543.0 (449.1, 1191.5) | |
| Type of primary treatment | 0.101 | ||
| Primary debulking | 8 (26.7) | 12 (48.0) | |
| Neoadjuvant chemotherapy | 22 (73.3) | 13 (52.0) | |
| Extent of cytoreductive surgery | 0.028 | ||
| Optimal | 7 (23.3) | 13 (52.0) | |
| Suboptimal | 23 (76.7) | 12 (48.0) | |
| Ascites | 0.803 | ||
| No | 13 (43.3) | 10 (40.0) | |
| Yes | 17 (56.7) | 15 (60.0) | |
| FIGO stage | 0.202c | ||
| Early | 0 (0.0) | 2 (8.0) | |
| Advanced | 30 (100.0) | 23 (92.0) | |
| Disease grade | 0.032 | ||
| Low grade | 5 (16.7) | 0 (0.0) | |
| High grade | 25 (83.3) | 25 (100.0) | |
| Histological type | 0.309 | ||
| Serous | 24 (80.0) | 17 (68.0) | |
| Non-serous | 6 (20.0) | 8 (32.0) | |
| Total | 30 (54.5) | 25 (45.5) |
Abbreviations: SD, standard deviation; IQR, interquartile range; BMI, body mass index; FIGO, international federation of obstetrics and gynaecology a Independent sample T-test; b Mann-Whitney U test; c Fisher’s exact test